Luca Cantini, Filippo Merloni, Silvia Rinaldi, Edoardo Lenci, Giulia Marcantognini, Tania Meletani, Ilaria Fiordoliva, Francesca Morgese, Mariangela Torniai, Giulia Ricci, Riccardo Giampieri, Rossana Berardi
Journal: Critical reviews in oncology/hematology 2020;151():102974
PMID: 32416348
BACKGROUND
Aim of this meta-analysis was to determine the relative risk (RR) of electrolyte disorders (EDs) in advanced non-small cell lung cancer (aNSCLC) patients treated with immune check-point inhibitors (ICIs).
METHODS
We searched for phase II/III randomized controlled trials (RCTs) comparing ICIs (alone or combined with chemotherapy) with standard chemotherapy in aNSCLC. Summary incidence and RR were calculated.
RESULTS
Six RCTs with data on all-grade hyponatremia were identified (n = 3257). The incidence was 8.7 % in the study group and 4.9 % in the control group (RR 1.78, 95 %CI 1.12-2.80). Looking at all-grade hypokalemia, 7 RCTs were included (n = 4119). Incidence was 10.4 % in ICIs-treated patients and 5.9 % in the control arms (RR 1.62, 95 % CI 1.30-2.02).
CONCLUSIONS
Treatment with ICIs in aNSCLC is associated with a significant increased risk of hyponatremia and hypokalemia compared to chemotherapy. Monitoring of electrolyte levels should be emphasized in this setting.
Copyright © 2020 Elsevier B.V. All rights reserved.
© Copyright 2026, Nutrition Evidence
NED wishes to thank the following organisations for their support:
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.